0.624

0.65% 0.004

Pre-market: .62 -0.004 -0.64%

Oragenics Inc (OGEN)

Overview News Price History Discussions Forecast Stock Split

Oragenics Inc stock is traded at $0.624, with a volume of 49,471. It is up +0.65% in the last 24 hours and up +6.05% over the past month. Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Previous Close:

$0.62

Open:

$0.62

24h Volume:

49,471

Relative Volume:

0.55

Market Cap:

$2.82M

Revenue:

$7,500

Net Income/Loss:

$-9.84M

P/E Ratio:

-0.109

EPS:

-5.7263

Net Cash Flow:

$-9.25M

1W Performance:

+3.24%

1M Performance:

+6.05%

6M Performance:

-25.40%

1Y Performance:

-85.69%

1-Day Range:

$0.615

$0.63

1-Week Range:

$0.575

$0.63

52-Week Range:

$0.5038

$4.85

Oragenics Inc Stock (OGEN) Company Profile

Name

Oragenics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

813-286-7900

Address

4902 Eisenhower Boulevard, Suite 125, Tampa, FL

Employee

Twitter

Next Earnings Date

2026-05-08

Latest SEC Filings

OGEN's Discussions on Twitter

Compare OGEN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OGEN Oragenics Inc	0.624	2.82M	7,500	-9.84M	-9.25M	-5.7263
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Oragenics Inc Stock (OGEN) Latest News

Jun 13, 2026

OGEN Q2 2023 Earnings: EPS Beat on Lower-than-Expected Loss, But Stock DeclinesEarnings Forecast Report - newsline.com

Jun 13, 2026

OGEN Q2 2023 Earnings: Loss Narrower Than Expected but No Revenue, Stock DeclinesQuarterly Earnings Report - newsline.com

Jun 13, 2026

Jun 12, 2026

OGEN Q2 2023 Earnings: Narrower Loss Drives 5% Bounce on Surprise BeatRevenue Growth Report - newsline.com

Jun 12, 2026

Jun 11, 2026

OGEN Q2 2023 Earnings: Smaller-Than-Expected Loss as Clinical Pipeline ProgressesProduct Revenue Analysis - newsline.com

Jun 11, 2026

Jun 09, 2026